Wells Fargo & Company Curis Inc Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.57 - $0.99 $129 - $224	227 Added 36.2%	854 $0
Q1 2023 May 12, 2023	BUY	$0.51 - $0.78 $5 - $7	10 Added 1.62%	627 $0
Q4 2022 Feb 13, 2023	BUY	$0.47 - $17.22 $20 - $757	44 Added 7.68%	617 $0
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $38 - $780	52 Added 9.98%	573 $0
Q2 2022 Aug 12, 2022	SELL	$0.71 - $2.43 $43,076 - $147,430	-60,671 Reduced 99.15%	521 $1,000
Q1 2022 May 16, 2022	SELL	$2.31 - $5.13 $63,816 - $141,721	-27,626 Reduced 31.1%	61,192 $146,000
Q4 2021 Feb 14, 2022	BUY	$4.45 - $8.09 $90,428 - $164,396	20,321 Added 29.67%	88,818 $423,000
Q3 2021 Nov 15, 2021	BUY	$6.94 - $8.85 $474,397 - $604,959	68,357 Added 48826.43%	68,497 $536,000
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $22 - $48	-3 Reduced 2.1%	140 $1,000
Q1 2021 May 13, 2021	SELL	$8.78 - $12.8 $2,967 - $4,326	-338 Reduced 70.27%	143 $2,000
Q4 2020 Feb 09, 2021	BUY	$1.08 - $8.2 $201 - $1,533	187 Added 63.61%	481 $4,000
Q3 2020 Nov 05, 2020	BUY	$0.95 - $1.42 $122 - $183	129 Added 78.18%	294 $0
Q2 2020 Aug 13, 2020	BUY	$0.63 - $1.7 $0 - $1	1 Added 0.61%	165 $0
Q1 2020 May 14, 2020	BUY	$0.67 - $1.85 $109 - $303	164 New	164 $0

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.